COVID-19 vaccine

BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

Retrieved on:

Monday, December 21, 2020

Articles, Medical research, Health sciences, Medicine, BioNTech, Societates Europaeae, BNT162b2, COVID-19 vaccine, Conference, Uğur Şahin

Mainz, Germany, December 21, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will hold a press conference including a video webcast on Tuesday, December 22, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.

Key Points:

Mainz, Germany, December 21, 2020 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will hold a press conference including a video webcast on Tuesday, December 22, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.
The event will be held virtual and in English:
Interested journalists may dial in 10-15 minutes before the conference starts.
They will be able to submit questions via an online tool.The press conference will be virtual only.
Participants may also access the press conference, including the video webcast, on https://biontech.de/ under "Events & Presentations" in the Investor & Media section of the website.

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

Retrieved on:

Monday, December 21, 2020

Medical research, Health sciences, Medicine, Health, COVID-19 vaccine, Pfizer, BioNTech, Uğur Şahin, Vaccine, BNT162b2, Kathrin Jansen

This achievement is also a testament to the successful collaboration with our partner Pfizer, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.

Key Points:

This achievement is also a testament to the successful collaboration with our partner Pfizer, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.
Pfizer and BioNTech are providing a vaccine transition option that enables trial participants 16 years and over who received the placebo to receive the vaccine as part of the study.
Pfizer and BioNTech are confident in their ability to deliver the vaccine to people in the EU.
Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series.

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

Retrieved on:

Monday, December 21, 2020

Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical research, Health sciences, Medicine, Health, COVID-19 vaccine, Pfizer, BioNTech, Uğur Şahin, Vaccine, BNT162b2, Kathrin Jansen

This achievement is also a testament to the successful collaboration with our partner Pfizer, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.

Key Points:

This achievement is also a testament to the successful collaboration with our partner Pfizer, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.
Pfizer and BioNTech are providing a vaccine transition option that enables trial participants 16 years and over who received the placebo to receive the vaccine as part of the study.
Pfizer and BioNTech are confident in their ability to deliver the vaccine to people in the EU.
Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series.

Granicus Launches Vaccine Communications Toolkit to Help Governments Maximize Vaccine Adoption and Efficacy

Retrieved on:

Monday, December 21, 2020

Vaccination, Medical specialties, Vaccine, Virology, Granicus, Medicine, Vaccines, Health care, COVID-19 vaccine

The toolkit includes several free tools, available to any local, state, or federal government organization, that are designed to accelerate vaccine communications strategies and boost their effectiveness.

Key Points:

The toolkit includes several free tools, available to any local, state, or federal government organization, that are designed to accelerate vaccine communications strategies and boost their effectiveness.
Building trust and transparency around vaccine administration poses one of the greatest and most important government communications challenges of our time, said Mark Hynes, CEO of Granicus.
With the Vaccine Communications Toolkit, governments will be able to formulate a cost-effective plan thats grounded in best practices and built to quickly drive action.
The Vaccine Communications Toolkit marks Granicus latest effort to support federal, state, and local governments through the COVID-19 crisis.

5 Things Hospitals Need to Know About Managing COVID-19 Vaccines From Wolters Kluwer

Retrieved on:

Monday, December 21, 2020

General Health, FDA, Hospitals, Health, Pharmaceutical, Medicine, Medical research, Health sciences, Medical specialties, COVID-19 vaccine, Vaccine, Vaccines, Clinical trials

Now that the FDA has approved two different COVID-19 vaccines for emergency use, Annie Lambert, PharmD, BCSCP, clinical program manager, Wolters Kluwer, Health advises that hospitals keep in mind the following five things when managing the vaccine doses:

Key Points:

Now that the FDA has approved two different COVID-19 vaccines for emergency use, Annie Lambert, PharmD, BCSCP, clinical program manager, Wolters Kluwer, Health advises that hospitals keep in mind the following five things when managing the vaccine doses:
This press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20201221005628/en/
Wolters Kluwer shares 5 things to help manage the COVID-19 vaccine.
(Graphic: Business Wire)
Hardcopy or Excel temperature monitoring and storage management tracking is not enough.
Update and schedule custom competencies on vaccine storage, dispensing,and administration
Report results effectively on compliance, completion volume, staff training, and quality
For additional information on how to manage COVID-19 vaccines visit here .

Welltok Is the COVID-19 Communications Engine for Vaccine Manufacturers, Insurers, Hospitals and More

Retrieved on:

Monday, December 21, 2020

Medicine, Medical specialties, Health sciences, Medical research, Vaccines, COVID-19 vaccine, Vaccine, Vaccination, Coronavirus disease, Global Advisory Committee on Vaccine Safety, Vaccination policy

Welltok , the consumer activation company, is playing an integral role as the communications engine for a number of the largest stakeholders across the healthcare industry.

Key Points:

Welltok , the consumer activation company, is playing an integral role as the communications engine for a number of the largest stakeholders across the healthcare industry.
Welltok's new COVID-19 vaccine resources will include awareness campaigns like "COVID-19: Get your Vaccination" and "Is the COVID-19 Vaccine Safe" as well as activity tracking for "Did you get your COVID-19 vaccine?"
It is also facilitating access to antibody tests, which will be important to administer alongside theCOVID vaccine.
"Welltok has helped companies across the healthcare industry activate their populations to improve their health and the health of their communities.

DGAP-News: European innovation reaches EU population: MIG Fonds' portfolio company BioNTech achieves positive CHMP opinion for the first COVID-19 and mRNA vaccine

Retrieved on:

Monday, December 21, 2020

Medicine, Medical research, Health sciences, Medical specialties, RNA, BioNTech, Societates Europaeae, RNA vaccine, Vaccine, COVID-19 vaccine, BNT162b2

European innovation reaches EU population: MIG Fonds' portfolio company BioNTech achieves positive CHMP opinion for the first COVID-19 and mRNA vaccine

Key Points:

European innovation reaches EU population: MIG Fonds' portfolio company BioNTech achieves positive CHMP opinion for the first COVID-19 and mRNA vaccine
The issuer is solely responsible for the content of this announcement.
European innovation reaches EU population: MIG Fonds' portfolio company BioNTech achieves positive CHMP opinion for the first COVID-19 and mRNA vaccine
- European community to benefit from European innovation and long-term VC investment strategies.
The positive recommendation represents the first for both a COVID-19 and mRNA vaccine in the European Union.
This positive recommendation is confirmation of the value in European science, technology and outstanding management teams, all backed by long-term European private risk-capital investors.

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

Retrieved on:

Monday, December 21, 2020

Medical research, Health sciences, Medicine, Life sciences, COVID-19 vaccine, Pfizer, BioNTech, Albert Bourla, BNT162b2, Operation Warp Speed

We are pleased with the Committees strong vote of confidence in our data, said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Key Points:

We are pleased with the Committees strong vote of confidence in our data, said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
The CHMP advisors based their positive opinion on the scientific evidence supporting the Pfizer-BioNTech COVID-19 vaccine, including data from a Phase 3 clinical study announced last month and published in The New England Journal of Medicine on December 10, 2020.
To date, the vaccine has been authorized or approved for emergency or temporary use in more than 15 countries.
Individuals who have received one dose of Pfizer-BioNTech COVID-19 vaccine should receive a second dose of Pfizer-BioNTech COVID-19 vaccine to complete the vaccination series.

Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine

Retrieved on:

Monday, December 21, 2020

Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical research, Health sciences, Medicine, Life sciences, COVID-19 vaccine, Pfizer, BioNTech, Albert Bourla, BNT162b2, Operation Warp Speed, Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech

We are pleased with the Committees strong vote of confidence in our data, said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

Key Points:

We are pleased with the Committees strong vote of confidence in our data, said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
The CHMP advisors based their positive opinion on the scientific evidence supporting the Pfizer-BioNTech COVID-19 Vaccine, including data from a Phase 3 clinical study announced last month and published in The New England Journal of Medicine on December 10, 2020.
To date, the vaccine has been authorized or approved for emergency use in more than 15 countries.
Individuals who have received one dose of Pfizer-BioNTech COVID-19 Vaccine should receive a second dose of Pfizer-BioNTech COVID-19 Vaccine to complete the vaccination series.

InterSystems Helps U.S. Department of Veterans Affairs Ensure Early Veteran Access to COVID-19 Vaccine

Retrieved on:

Monday, December 21, 2020

Since COVID-19 arrived in the United States in early 2020, the U.S. Department of Veterans Affairs (VA) has been diligently working to protect one of the nations most vulnerable populations: veterans.

Key Points:

Since COVID-19 arrived in the United States in early 2020, the U.S. Department of Veterans Affairs (VA) has been diligently working to protect one of the nations most vulnerable populations: veterans.
The nationwide deployment of the COVID-19 vaccine is one of the largest undertakings in the history of the modern healthcare industry.
The effective distribution of the vaccine requires timely, clean and actionable data to identify and ensure the most at-risk communities are first in line.
In Q2 2020, VA launched InterSystems VDIF EP (Veterans Data Integration and Federation Enterprise Platform) based on InterSystems HealthShare to develop longitudinal patient records, which are now available to providers within Veterans Health Administration (VHA).